OSR Holdings, Inc.

OSR Health, Inc. is a healthcare holding company that develops therapies and healthcare solutions in the United States, Europe, and Korea. Its pipeline includes immunotherapy products such as VXM01, an immuno-oncology candidate for glioblastoma that has completed a phase 2 clinical trial, and preclinical candidates VXM04 for mesothelin, VXM06 for Wilms Tumor Protein (WT1), VXM08 for Carcinoembryonic antigen (CEA), and VXM10 for PD-L1. The company also develops design-augmented (DA) biologics, including DRT-102, a clinical-stage asset for spinal fusion, and DRT-101, a preclinical-stage asset for osteoarthritis, and distributes neurovascular intervention medical devices and systems. Formerly known as OSR Holdings, Inc., it changed its name to OSR Health, Inc. in June 2026, was incorporated in 2020, and is based in Bellevue, Washington.